MAIA (MAIA Biotechnology) Change In Payables And Accrued Expense : $-0.55 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Change In Payables And Accrued Expense?

MAIA Biotechnology's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.09 Mil. It means MAIA Biotechnology's Accounts Payable & Accrued Expense increased by $0.09 Mil from Jun. 2024 to Sep. 2024 .

MAIA Biotechnology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $2.64 Mil. It means MAIA Biotechnology's Accounts Payable & Accrued Expense increased by $2.64 Mil from Dec. 2022 to Dec. 2023 .

MAIA Biotechnology Change In Payables And Accrued Expense Historical Data

The historical data trend for MAIA Biotechnology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Change In Payables And Accrued Expense Chart

MAIA Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

0.83

1.80

1.13

2.64

MAIA Biotechnology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial											0.88	0.78	-0.04	-1.39	0.09

MAIA Biotechnology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

MAIA Biotechnology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060

Website

https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Executives

Stan Smith	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Steven M Chaouki	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Cristian Luput	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie	director, 10 percent owner	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc	director, 10 percent owner, officer: Chief Executive Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire	officer: Chief Financial Officer	6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene	director	500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov	officer: Chief Scientific Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea	officer: Chief Medical Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606